Program

Monday, October 6, 2025
8:00 AM																Masterclass Session I Gideon Hirschfield & Or Steg Saban Gideon Hirschfield, The Autoimmune and Rare Liver Disease Programme Or Stegsaban, The Hospital for Sick Children
10:00 AM																Morning Break
10:30 AM																Masterclass Session II *Orlee Guttman* Orlee Guttman, British Columbia Children's Hospital
12:00 PM																Lunch Break
12:15 PM																Industry Symposium Sponsored Symposia Program
1:30 PM																STC Session I - Genetic cholestasis The biologic mechanisms and pathophysiology of cholestasis - Andréanne Zizzo Adult presentations of "pediatric" genetic cholestatic diseases - Silvia Vilarinho Ductal plate malformations and ciliopathies: a primer for all! - *Jessica Wen* New and emerging therapies in cholestatic liver disease - *Richard Thompson* Round Table & Q&A Andreanne Zizzo, Western University, Children's Hospital, LHSC Silvia Vilarinho, Yale University Jessica Wen, The Children's Hospital of Philadelphia Richard Thompson, King's College London
3:30 PM																Afternoon Break
4:00 PM																STC Session II - Autoimmune Liver Disease Primer on primary biliary cholangitis: biology and presentation - *Hin Hin Ko* New therapies for primary biliary cholangitis - *Gideon Hirschfield* Primary sclerosing cholangitis: where do we stand in the adult world - *Kristel Leung* Recurrence of autoimmune liver disease post transplant - Rahima Bhanji Autoimmune hepatitis : what treatment gaps remain? - Aldo Montano Loza Q&A Hin Hin Ko, University of British Columbia Gideon Hirschfield, The Autoimmune and Rare Liver Disease Programme Kristel Leung, Queen’s University Rahima Bhanji, University of Alberta Aldo Montanoloza, University of Alberta
6:00 PM																Reception
Tuesday, October 7, 2025
7:00 AM																Industry Symposium (Clone) Sponsored Symposia Program
8:00 AM																STC Session III - Controversies in treatment for rare liver disease "Overlap" syndromes: Is it time for adult physicians to believe pediatric pediatric conditions - Nanda Kerkar Steroid minimization in childhood autoimmune liver disease - Or Steg Saban Microbiome manipulation and GI-Liver disease - *Richard Kellermayer* Treatment and management options in intrahepatic cholestasis of pregnancy - *Saumya Jayakumar* Transition of hepatology patients from pediatric to adult care - *Susan Gilmour* Q&A Nanda Kerkar, Massachusetts General Brighaml for Children Or Stegsaban, The Hospital for Sick Children Richard Kellermayer, Baylor College of Medicine Saumya Jayakumar, University of Alberta Susan Gilmour, University of Alberta
10:00 AM																Morning Break
10:30 AM																STC Session IV - Pot-pourri Cystic fibrosis liver disease in the era of Trikafta - *Michael Narkewicz* Alpha-1 antitrypsin deficiency: will molecular therapy change outcomes? - Jean-Phillipe Wallach Hepatitis Delta: entering a new era - *Carla Coffin* IgG4 disease: a case-based discussion on treatments now and emerging - Gideon Hirschfield & Natassia Tan Vascular Disorders of the Liver: The Role of Interventional Radiology Q&A Michael Narkewicz, Children's Hospital Colorado and University of Colorado School of Medicine Jean-Philippe Wallach, University of British Columbia Carla Coffin, University of Calgary Natassia Tan, University Health Network
12:30 PM																Break
1:00 PM																Joint CASL & CST Liver Forum Opening Remarks Liver Forum Session 1 - MELD and MELD Alternatives The Case for Change: Where MELD Fails Alternative Models for Organ Allocation: International and Canadian Perspectives Panel Discussion Q&A Liver Forum Session 2 - Immunosuppression in Liver Transplantation To Induce or Not to Induce: Evolving Practices in 2025 Maintenance Strategies: Balancing Efficacy and Toxicity Diagnosis and Management of Antibody-Mediated Rejection in Liver Transplantation Panel Discussion Q&A Liver Forum Session 3 - Expanding the Donor Pool NRP in DCD: The Canadian Experience and Ethical Frameworks Ex-vivo Liver Perfusion: Clinical Experience and Research Priorities How Should Canada Adopt and Scale These Technologies? - Panel Discussion